Drug and alcohol misuse result in immense Drug and alcohol misuse result in immense harm at both individual and societal level. harm at both individual and societal level. Our understanding of the neuropharmaOur understanding of the neuropharmacology of these disorders is increasing cology of these disorders is increasing through the use of approaches such as through the use of approaches such as neuroimaging and gene targeting and the neuroimaging and gene targeting and the availability of specific receptor agonists availability of specific receptor agonists and antagonists. Our aim here is to describe and antagonists. Our aim here is to describe some interesting new findings that are some interesting new findings that are likely to inform advances in treatment. likely to inform advances in treatment.
THE DOPAMINERGIC THE DOPAMINERGIC PATHWAY PATHWAY Reward Reward
Over the past 20 years there has been Over the past 20 years there has been immense interest in the mesolimbic dopamiimmense interest in the mesolimbic dopaminergic system; most drugs of misuse (except nergic system; most drugs of misuse (except benzodiazepines) increase dopamine here. It benzodiazepines) increase dopamine here. It is widely accepted that increased levels of is widely accepted that increased levels of dopamine in the nucleus accumbens are dopamine in the nucleus accumbens are key in mediating the rewarding effects or key in mediating the rewarding effects or positive reinforcement of drugs of misuse positive reinforcement of drugs of misuse (Koob & Le Moal, 2001) . Evidence is still (Koob & Le Moal, 2001) . Evidence is still accruing to support this. For instance, alcoaccruing to support this. For instance, alcohol and morphine are no longer rewarding hol and morphine are no longer rewarding in mice lacking the D in mice lacking the D 2 2 receptor (D receptor (D 2 2 knockknockout mice; Maldonado out mice; Maldonado et al et al, 1997; Risinger , 1997; Risinger et al et al, 2000) . In humans, Volkow , 2000) . In humans, Volkow et al et al (1999) showed in a series of neuroimaging (1999) showed in a series of neuroimaging studies using cocaine or methylphenidate studies using cocaine or methylphenidate that increased dopamine levels in the brain that increased dopamine levels in the brain were associated with euphoria and pleasure. were associated with euphoria and pleasure. Interestingly, low levels of dopamine D Interestingly, low levels of dopamine D 2 2 receptors were associated with pleasure receptors were associated with pleasure after methylphenidate in drug-naıve indiviafter methylphenidate in drug-naïve individuals, whereas high receptor levels were duals, whereas high receptor levels were associated with unpleasant feelings. This associated with unpleasant feelings. This study gives us an insight into the role of study gives us an insight into the role of neurobiology in explaining why drug use neurobiology in explaining why drug use for some people is pleasurable and likely for some people is pleasurable and likely to be repeated and for others is unpleasant to be repeated and for others is unpleasant and not repeated. and not repeated.
Anticipation Anticipation
The role of dopamine in addiction is now The role of dopamine in addiction is now recognised as critical in anticipation and recognised as critical in anticipation and withdrawal as well. In an elegant series of withdrawal as well. In an elegant series of experiments, Schultz (2001) found that in experiments, Schultz (2001) found that in primates trained to associate a cue with a primates trained to associate a cue with a pleasurable experience (food), increased pleasurable experience (food), increased dopaminergic activity was seen in response dopaminergic activity was seen in response to the cue and not to the food. If the food to the cue and not to the food. If the food was not then presented, dopaminergic was not then presented, dopaminergic function dropped. Reduced dopaminergic function dropped. Reduced dopaminergic function is thought to be associated with function is thought to be associated with negative affect (e.g. dysphoria). Thus, an negative affect (e.g. dysphoria). Thus, an individual with an addiction may see a individual with an addiction may see a 'cue' (e.g. a public house, mirror or needle) 'cue' (e.g. a public house, mirror or needle) and if their drug of choice is not available and if their drug of choice is not available may feel dysphoric, which is likely to inmay feel dysphoric, which is likely to increase the drive to obtain the drug. crease the drive to obtain the drug.
Withdrawal Withdrawal
Reduced dopaminergic function has been Reduced dopaminergic function has been seen in withdrawal and early abstinence seen in withdrawal and early abstinence from many drugs of misuse. Neuroimaging from many drugs of misuse. Neuroimaging studies in cocaine, opiate and alcohol studies in cocaine, opiate and alcohol addictions have revealed reduced levels of addictions have revealed reduced levels of dopamine D dopamine D 2 2 receptors, which may recover receptors, which may recover to some extent during abstinence, but have to some extent during abstinence, but have been shown to persist for months (Volkow been shown to persist for months (Volkow et al et al, 1999) . Early stages of abstinence are , 1999). Early stages of abstinence are associated with elevated levels of craving, associated with elevated levels of craving, drug-seeking and risk of relapse, and it is drug-seeking and risk of relapse, and it is likely that hypodopaminergic function likely that hypodopaminergic function plays a mediating role. Presumably the plays a mediating role. Presumably the release of dopamine produced by the drug release of dopamine produced by the drug of choice provides relief from withdrawal, of choice provides relief from withdrawal, although this has not yet been studied. although this has not yet been studied.
Pharmacotherapy (Table 1) Pharmacotherapy (Table 1) Because of the pre-eminence of the dopaBecause of the pre-eminence of the dopaminergic reward system in addiction, this minergic reward system in addiction, this has been a target for pharmacotherapy, has been a target for pharmacotherapy, but with mixed results. One strategy, for but with mixed results. One strategy, for instance, has been to block the binding of instance, has been to block the binding of cocaine to the dopamine transporter site cocaine to the dopamine transporter site (Nutt, 1993) . In cocaine addiction, the de- (Nutt, 1993) . In cocaine addiction, the development of dopaminergic partial agonists velopment of dopaminergic partial agonists at the D at the D 3 3 receptor, such as BP-897, receptor, such as BP-897, currently holds some promise. In rats, BPcurrently holds some promise. In rats, BP-897 inhibits cocaine-seeking behaviour in 897 inhibits cocaine-seeking behaviour in response to cues (Pilla response to cues (Pilla et al et al, 1999) . As a , 1999 One drug that affects the dopaminergic One drug that affects the dopaminergic system and has proven efficacy in the treatsystem and has proven efficacy in the treatment of nicotine addiction is bupropion ment of nicotine addiction is bupropion (Jorenby (Jorenby et al et al, 1999) . The exact mechanism , 1999). The exact mechanism underlying this effect still has to be fully underlying this effect still has to be fully characterised; however, it has been shown characterised; however, it has been shown that bupropion increases dopamine and that bupropion increases dopamine and noradrenaline levels by acting as an uptake noradrenaline levels by acting as an uptake inhibitor (Ascher inhibitor (Ascher et al et al, 1995) . , 1995).
Related systems involved in reward Related systems involved in reward
Our understanding of other neurotransOur understanding of other neurotransmitter systems that are involved in reward mitter systems that are involved in reward and that may modulate dopaminergic and that may modulate dopaminergic activity provides further targets for activity provides further targets for pharmacotherapy. pharmacotherapy.
Opioids Opioids
The opioid system has three receptor The opioid system has three receptor subtypes: mu, kappa and delta. The mu subtypes: mu, kappa and delta. The mu subtype appears to be key in opiate subtype appears to be key in opiate addiction: for mice lacking this receptor, addiction: for mice lacking this receptor, morphine is no longer rewarding or reinformorphine is no longer rewarding or reinforcing (Kieffer, 1999) . In addition, a morcing (Kieffer, 1999) . In addition, a morphine withdrawal syndrome is not seen in phine withdrawal syndrome is not seen in these animals. Neuroimaging studies sugthese animals. Neuroimaging studies suggest that alterations in mu opiate receptor gest that alterations in mu opiate receptor levels may be fundamental to addiction. levels may be fundamental to addiction. Using [ Using [ (2000) found increased receptor levels in the anterior cingulate in recently abstinent the anterior cingulate in recently abstinent humans addicted to cocaine or opiates. This humans addicted to cocaine or opiates. This may reflect elevated mu opiate receptor may reflect elevated mu opiate receptor levels or decreased endogenous opioid levels or decreased endogenous opioid levels. In either case, craving may result. levels. In either case, craving may result.
Roles for kappa and delta opiate recepRoles for kappa and delta opiate receptors in addiction are also evident. Unlike tors in addiction are also evident. Unlike mu receptors, kappa receptor stimulation mu receptors, kappa receptor stimulation reduces dopamine function in the nucleus reduces dopamine function in the nucleus accumbens. This may possibly result in dysaccumbens. This may possibly result in dysphoria. In animal models, delta antagonists phoria. In animal models, delta antagonists can reduce self-administration of alcohol, can reduce self-administration of alcohol, suggesting that this receptor also plays a suggesting that this receptor also plays a key role in reinforcement. key role in reinforcement.
Naltrexone is a long-acting opiate Naltrexone is a long-acting opiate antagonist. Its use in opiate addiction is antagonist. Its use in opiate addiction is based on its ability to antagonise any effects based on its ability to antagonise any effects of opiates. However, in alcoholism the effiof opiates. However, in alcoholism the efficacy of naltrexone is thought to be a concacy of naltrexone is thought to be a consequence of its ability to block the actions sequence of its ability to block the actions of endorphins that are released by alcohol of endorphins that are released by alcohol and that mediate pleasure (Herz, 1997) . and that mediate pleasure (Herz, 1997).
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Glutamate Glutamate
Glutamate is the brain's principal Glutamate is the brain's principal excitatory neurotransmitter for which excitatory neurotransmitter for which there are three receptors -the ion channels there are three receptors -the ion channels N N-methyl--methyl-D D-aspartate (NMDA), alpha--aspartate (NMDA), alphaamino-3-hydroxy-5-methyl-isoxazole-4-amino-3-hydroxy-5-methyl-isoxazole-4-propionate (AMPA) and kainate -and also propionate (AMPA) and kainate -and also another receptor family which is coupled to another receptor family which is coupled to G-proteins and the second (metabotropic) G-proteins and the second (metabotropic) messenger system. Glutamatergic neurons messenger system. Glutamatergic neurons from the prefrontal cortex and amygdala from the prefrontal cortex and amygdala project onto the mesolimbic reward project onto the mesolimbic reward pathway, from which reciprocal dopapathway, from which reciprocal dopaminergic projections arise (Louk minergic projections arise (Louk et al et al, , 2000) . There is evidence that the glutama-2000). There is evidence that the glutamatergic projection from the prefrontal cortex tergic projection from the prefrontal cortex to the nucleus accumbens plays a to the nucleus accumbens plays a role in role in the reinstatement of stimulantthe reinstatement of stimulant-seeking seeking behaviour. behaviour.
The NMDA receptor has been impliThe NMDA receptor has been implicated in nicotine, ethanol, benzodiazepine cated in nicotine, ethanol, benzodiazepine and cannabinoid addiction (Wolf, 1998) . and cannabinoid addiction (Wolf, 1998) . For example, NMDA antagonists inhibit For example, NMDA antagonists inhibit sensitisation (i.e. enhanced responses) to stisensitisation (i.e. enhanced responses) to stimulants such as cocaine and amphetamine mulants such as cocaine and amphetamine and the development of opioid dependence. and the development of opioid dependence. Not all NMDA antagonists are clinically Not all NMDA antagonists are clinically useful, owing to their psychomimetic propuseful, owing to their psychomimetic properties (cf. ketamine, phencyclidine). Nevererties (cf. ketamine, phencyclidine). Nevertheless, memantine is a non-competitive theless, memantine is a non-competitive NMDA receptor antagonist, used to treat NMDA receptor antagonist, used to treat neurological disorders, which has recently neurological disorders, which has recently been shown to attenuate naloxone-precipibeen shown to attenuate naloxone-precipitated withdrawal in humans addicted to tated withdrawal in humans addicted to opiates (Bisaga opiates (Bisaga et al et al, 2001) . , 2001 ). There is recent evidence to suggest an There is recent evidence to suggest an important role for other glutamate recepimportant role for other glutamate receptors, such as the metabotropic receptor, tors, such as the metabotropic receptor, that may be independent of the dopathat may be independent of the dopaminergic system. In mice lacking the mGlu5 minergic system. In mice lacking the mGlu5 subtype of the metabotropic glutamatergic subtype of the metabotropic glutamatergic receptor, cocaine still increases dopamine receptor, cocaine still increases dopamine in the nucleus accumbens; but the mice do in the nucleus accumbens; but the mice do not self-administer cocaine or show not self-administer cocaine or show increased locomotor activity (Chiamulera increased locomotor activity (Chiamulera et al et al, 2001) .
, 2001).
Cannabinoids Cannabinoids
Opioids and cannabinoids share some Opioids and cannabinoids share some pharmacological properties producing pharmacological properties producing effects such as sedation, hypothermia effects such as sedation, hypothermia and anti-nociception. In addition, there is and anti-nociception. (Ameri, 1999) . In mice lacking the ganglia (Ameri, 1999 
ALCOHOL WITHDR AWAL: ALCOHOL WITHDR AWAL: THE ROLE OF GLUTAMATE THE ROLE OF GLUTAMATE
The neurobiology of alcoholism involves The neurobiology of alcoholism involves many different neurotransmitters, but key many different neurotransmitters, but key are the gamma-aminobutyric acid (GABA)-are the gamma-aminobutyric acid (GABA)-ergic system and the glutamatergic system ergic system and the glutamatergic system (Nutt, 1999) . In alcohol withdrawal, (Nutt, 1999) . In alcohol withdrawal, increased glutamatergic NMDA function increased glutamatergic NMDA function is present and is thought to be involved in is present and is thought to be involved in seizures and cell death, by means of seizures and cell death, by means of increased Ca increased Ca 2+ 2+ influx through its channel influx through its channel and low Mg and low Mg 2+ 2+ . The hippocampus appears
. The hippocampus appears to be a critical site for such glutamatergic to be a critical site for such glutamatergic hyperactivity. Acamprosate, a taurine derihyperactivity. Acamprosate, a taurine derivative, is increasingly used to maintain vative, is increasingly used to maintain abstinence from alcohol as it has been abstinence from alcohol as it has been shown to double abstinence rates. How shown to double abstinence rates. How acamprosate achieves its therapeutic effect acamprosate achieves its therapeutic effect has not yet been fully characterised; it has not yet been fully characterised; it antagonises the NMDA receptor (possibly antagonises the NMDA receptor (possibly through the polyamine site). Acamprosate through the polyamine site). Acamprosate also reduces glutamate levels and may be also reduces glutamate levels and may be neuroprotective (Dahchour & De Witte, neuroprotective (Dahchour & De Witte, 2000) . If such neuroprotection occurs in 2000). If such neuroprotection occurs in humans, this would have important implihumans, this would have important implications for the treatment of alcoholism; cations for the treatment of alcoholism; currently some workers advocate starting currently some workers advocate starting acamprosate with detoxification. acamprosate with detoxification.
OPIOID DEPENDENCE : OPIOID DEPENDENCE : WHAT OTHER WHAT OTHER NEUROTR ANSMIT TER NEUROTR ANSMIT TER SYSTEMS ARE INVOLVED? SYSTEMS ARE INVOLVED?
As described above, the mu opiate receptor As described above, the mu opiate receptor plays a key role in opiate reward, but many plays a key role in opiate reward, but many of the mechanisms underlying opiate tolerof the mechanisms underlying opiate tolerance, dependence and withdrawal remain ance, dependence and withdrawal remain elusive. As the opiate receptor may not elusive. As the opiate receptor may not change with chronic opiate exposure, change with chronic opiate exposure, changes 'downstream' of the receptor may changes 'downstream' of the receptor may be more critical. For example, noradrenerbe more critical. For example, noradrenergic overactivity is seen in opiate withdrawal gic overactivity is seen in opiate withdrawal and can be treated with and can be treated with a a 2 2 agonists such as agonists such as lofexidine or clonidine (Strang lofexidine or clonidine (Strang et al et al, 1999) . , 1999). In the treatment of opiate addiction, In the treatment of opiate addiction, methadone is the most commonly premethadone is the most commonly prescribed drug, although the use of buprenorscribed drug, although the use of buprenorphine is increasing. Methadone (like phine is increasing. Methadone (like heroin) is a full agonist at the mu receptor, heroin) is a full agonist at the mu receptor, whereas buprenorphine is a mu partial whereas buprenorphine is a mu partial agonist. Partial agonists give lower levels agonist. Partial agonists give lower levels of response at maximal receptor occuof response at maximal receptor occupancy. Also, when a partial agonist occupancy. Also, when a partial agonist occupies receptors, fewer are available for a pies receptors, fewer are available for a full agonist (e.g. heroin). The partial agofull agonist (e.g. heroin). The partial agonist is therefore acting as an antagonist. nist is therefore acting as an antagonist. Consequently, buprenorphine will stimuConsequently, buprenorphine will stimulate the mu opioid receptor, but not maxilate the mu opioid receptor, but not maximally (hence, there is less risk of mally (hence, there is less risk of respiratory depression in overdose), and respiratory depression in overdose), and will also prevent the effects of heroin taken will also prevent the effects of heroin taken 'on top'. In addition, its longer half-life al-'on top'. In addition, its longer half-life allows less than daily dosing, an advantage lows less than daily dosing, an advantage in supervised consumption. in supervised consumption.
ECSTASY: THE 5 -HT SYSTEM ECSTASY: THE 5 -HT SYSTEM AND NEUROTOXICITY AND NEUROTOXICITY Ecstasy (3,4-methylenedioxymethamphetaEcstasy (3,4-methylenedioxymethamphetamine or MDMA) and its derivatives MDA mine or MDMA) and its derivatives MDA (Adam) and MDEA (Eve) have both (Adam) and MDEA (Eve) have both stimulant and hallucinogenic properties. stimulant and hallucinogenic properties. Acutely, MDMA increases 5-hydroxytrypAcutely, MDMA increases 5-hydroxytryptamine (5-HT or serotonin) levels, and, tamine (5-HT or serotonin) levels, and, to a lesser extent, dopamine levels, by to a lesser extent, dopamine levels, by stimulating release and inhibiting uptake. stimulating release and inhibiting uptake.
Animal studies have revealed ecstasy Animal studies have revealed ecstasy and its derivatives to be neurotoxic to and its derivatives to be neurotoxic to serotonergic neurons (MDA serotonergic neurons (MDA4 4MDMA MDMA4 4 MDEA), but it is controversial whether and MDEA), but it is controversial whether and to what extent the same occurs in man (Boot to what extent the same occurs in man (Boot et al et al, 2000) . Neuroimaging studies using , 2000). Neuroimaging studies using PET and single photon emission tomo-PET and single photon emission tomography (SPET) to measure 5-HT transgraphy (SPET) to measure 5-HT transporter levels in persons who are regular porter levels in persons who are regular heavy ecstasy users report reduced levels. heavy ecstasy users report reduced levels. However, methodological questions about However, methodological questions about the tracer, contribution of blood flow and the tracer, contribution of blood flow and choice of subjects necessarily limit these choice of subjects necessarily limit these conclusions (Semple conclusions (Semple et al et al, 1999; Reneman , 1999; Reneman et al et al, 2001) . There is some evidence for cog-, 2001). There is some evidence for cognitive impairments in individuals using nitive impairments in individuals using ecstasy which may persist after a period of ecstasy which may persist after a period of chronic use, and it is not clear how reversible chronic use, and it is not clear how reversible these are with time. In animal models, fluoxthese are with time. In animal models, fluoxetine has been shown to be neuroprotective, etine has been shown to be neuroprotective, apparently by blocking ecstasy uptake into apparently by blocking ecstasy uptake into 5-HT neurons, but it is unknown whether 5-HT neurons, but it is unknown whether this protective effect occurs in humans. this protective effect occurs in humans.
THE GABAERGIC SYSTEM: THE GABAERGIC SYSTEM: TARGET FOR SEDATIVES TARGET FOR SEDATIVES
The most widely misused group of drugs The most widely misused group of drugs acting on this system are the acting on this system are the benzodiazepines. These modulate the benzodiazepines. These modulate the GABA-benzodiazepine receptor, increasing GABA-benzodiazepine receptor, increasing the action of GABA, and so result in greater the action of GABA, and so result in greater inhibitory activity in the brain (Nutt & inhibitory activity in the brain (Nutt & Malizia, 2001) . In contrast to other drugs Malizia, 2001) . In contrast to other drugs of misuse, benzodia of misuse, benzodiazepines do not increase zepines do not increase dopamine release dopamine release in the mesolimbic sysin the mesolimbic system. Misuse of these drugs is probably dritem. Misuse of these drugs is probably driven by the development of tolerance ven by the development of tolerance leading to withdrawal if these drugs are leading to withdrawal if these drugs are not taken. Benzodiazepine dependence in not taken. Benzodiazepine dependence in the context of drug addiction, where large the context of drug addiction, where large doses of benzodiazepines are taken, is disdoses of benzodiazepines are taken, is distinct from dependence in the context of tinct from dependence in the context of long-term use of a prescribed benzodiazelong-term use of a prescribed benzodiazepine for anxiety. pine for anxiety.
Gamma-hydroxybutyrate (GHB) is a Gamma-hydroxybutyrate (GHB) is a short-chain fatty acid which, among other short-chain fatty acid which, among other effects, enhances GABAergic function. effects, enhances GABAergic function. GHB inhibits central nervous system activ-GHB inhibits central nervous system activity and is a sedative but is also euphoriity and is a sedative but is also euphorigenic, presumably being linked to an genic, presumably being linked to an increase in dopamine (Nicholson & Balster, increase in dopamine (Nicholson & Balster, 2001) . It is increasingly used as a 'recrea-2001) . It is increasingly used as a 'recreational club drug' and there is growing contional club drug' and there is growing concern about its safety, particularly when cern about its safety, particularly when combined with alcohol to render women combined with alcohol to render women vulnerable to sexual assault. vulnerable to sexual assault.
CONCLUSION CONCLUSION
This is an exciting time in addiction as the This is an exciting time in addiction as the neurobiology of addiction disorders beneurobiology of addiction disorders becomes clearer. Such characterisation not comes clearer. Such characterisation not only provides a greater understanding of only provides a greater understanding of why people become addicted and what why people become addicted and what happens to the brain after a period of subhappens to the brain after a period of substance misuse, but also allows better understance misuse, but also allows better understanding of current pharmacotherapies and, standing of current pharmacotherapies and, we hope, the development of new treatwe hope, the development of new treatments. ments.
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